LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
Titel:
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
Auteur:
Bardia, A. Juric, D. Shimizu, T. Tolcher, A. Karim, R. Spira, A. Mukohara, T. Lisberg, A.E. Kogawa, T. Krop, I. Papadopoulos, K.P. Hamilton, E. Damodaran, S. Greenberg, J. Gu, W. Kobayashi, F. Guevara, F. Jikoh, T. Kawasaki, Y. Meric-Bernstam, F.